RT Journal Article
SR Electronic
T1 Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.08.22278576
DO 10.1101/2022.08.08.22278576
A1 Turtle, Lance
A1 Thorpe, Mathew
A1 Drake, Thomas M
A1 Swets, Maaike
A1 Palmieri, Carlo
A1 Russell, Clark D
A1 Ho, Antonia
A1 Aston, Stephen
A1 Wootton, Daniel G
A1 Richter, Alex
A1 de Silva, Thushan I
A1 Hardwick, Hayley E
A1 Leeming, Gary
A1 Law, Andy
A1 Openshaw, Peter JM
A1 Harrison, Ewen M
A1 ,
A1 Baillie, J Kenneth
A1 Semple, Malcolm G
A1 Docherty, Annemarie B
YR 2022
UL http://medrxiv.org/content/early/2022/08/11/2022.08.08.22278576.abstract
AB Background Immunocompromised patients may be at higher risk of mortality if hospitalised with COVID-19 compared with immunocompetent patients. However, previous studies have been contradictory. We aimed to determine whether immunocompromised patients were at greater risk of in-hospital death, and how this risk changed over the pandemic.Methods We included patients >=19yrs with symptomatic community-acquired COVID-19 recruited to the ISARIC WHO Clinical Characterisation Protocol UK. We defined immunocompromise as: immunosuppressant medication preadmission, cancer treatment, organ transplant, HIV, or congenital immunodeficiency. We used logistic regression to compare the risk of death in both groups, adjusting for age, sex, deprivation, ethnicity, vaccination and co-morbidities. We used Bayesian logistic regression to explore mortality over time.Findings Between 17/01/2020 and 28/02/2022 we recruited 156,552 eligible patients, of whom 21,954 (14%) were immunocompromised. 29% (n=6,499) of immunocompromised and 21% (n=28,608) of immunocompetent patients died in hospital. The odds of in-hospital mortality were elevated for immunocompromised patients (adjOR 1.44, 95% CI 1.39-1.50, p<0.001). As the pandemic progressed, in-hospital mortality reduced more slowly for immunocompromised patients than for immunocompetent patients. This was particularly evident with increasing age: the probability of the reduction in hospital mortality being less for immunocompromised patients aged 50-69yrs was 88% for men and 83% for women, and for those >80yrs was 99% for men, and 98% for women.Conclusions Immunocompromised patients remain at elevated risk of death from COVID-19. Targeted measures such as additional vaccine doses and monoclonal antibodies should be considered for this group.Funding National Institute for Health Research; Medical Research Council; Chief Scientist Office, Scotland.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://isaric4c.net Funding StatementNIHR (https://www.nihr.ac.uk) award CO-CIN-01 to MGS, MRC (https://www.ukri.org/councils/mrc/) award MC_PC_19059 to JKB and MR/V028979/1 to CP/LT Chief Scientist Office, Scotland (https://www.cso.scot.nhs.uk), award to ABD (no ref number) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the South Central - Oxford C Research Ethics Committee in England (Ref: 13/SC/0149) and by the Scotland A Research Ethics Committee (Ref: 20/SS/0028).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be shared publicly because of they contain person identifiable information. ISARIC4C welcomes applications for data and material access through our Independent Data and Material Access Committee (https://isaric4c.net) for researchers who meet the criteria for access to confidential data. https://isaric4c.net